Indian CDMO Companies Must Level Up for Opportunity from US Biosecure Act
How Syngene Is Revving Up Capabilities In ADCs, PROTACs
Bharat Eyes Global Biomanufacturing Dominance: Boosting Innovation, Collaboration & Entrepreneurship with BioE3 Policy
Forging Ahead in Formulation
Syngene expands supply chain with China-free options
US Biosecure Act: Impact on Indian pharma companies
Evolving trends for Big Pharma to benefit Syngene, says CFO Sibaji Biswas
Pharma & biotech industry propels ESG implementation with concerns over climate change & global supply disruptions
India seeks a seat at the drug services table
Integrating Strategies for Formulation Success